California-based Emmecell announced receipt of US FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002, its investigational allogeneic cultured human corneal endothelial cell therapy delivered via the company’s proprietary Magnetic Cell Delivery platform, for the treatment of corneal edema secondary to corneal endothelial dysfunction. The EO2002 RMAT designation represents the first major regulatory recognition for the program and positions Emmecell to enter enhanced dialogue with the FDA as it prepares to advance the EMERALD pivotal study.
RMAT designation is a specialized pathway for cell therapies, gene therapies, and tissue-engineered products intended to treat serious conditions where preliminary clinical evidence indicates potential to address unmet medical needs. It carries the benefits of Breakthrough Therapy designation — including intensive FDA guidance, senior agency involvement, and eligibility for accelerated approval and priority review — plus additional collaboration on manufacturing strategy and clinical trial design.
For Emmecell, the award follows a recently closed strategic financing round that included participation from Bausch + Lomb, as well as the appointment of an experienced ophthalmic commercial executive as chief executive officer.
EO2002 works by delivering magnetically labeled allogeneic human corneal endothelial cells via intracameral injection. A magnetic positioning step following injection is designed to localize and retain the cells at the posterior corneal surface, where they are intended to repopulate the endothelial layer and restore its fluid-pumping function. Corneal endothelial cells do not regenerate naturally; when lost through disease or surgical trauma, the result is progressive corneal swelling, clouding, and vision loss. The current standard of care — endothelial keratoplasty — is constrained by donor tissue availability, with an estimated one healthy donor cornea available for every 70 diseased eyes globally. EO2002’s non-surgical, injection-based approach is designed to treat patients who do not have disease severe enough to warrant transplant surgery, a population estimated to represent approximately 90% of those with symptomatic corneal edema.
The clinical evidence supporting the EO2002 RMAT designation derives from EMME-001, a 21-patient randomized, double-masked, US-based multicenter Phase I extension study that completed last patient last visit in October 2024. Topline results reported in November 2024 showed that patients in the 150,000-cell cohort achieved a mean gain of 11 letters in best corrected visual acuity (BCVA) at six months, with 38% of subjects achieving at least a 15-letter improvement — a threshold commonly used as a clinically meaningful responder criterion in corneal edema trials. The RMAT designation is expected to facilitate FDA interactions as Emmecell prepares the EMERALD pivotal program, potentially accelerating development of what could become a minimally invasive alternative to endothelial keratoplasty for corneal endothelial disease.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team
Explore more at AllSci News: https://allsci.com/news/